BioAge Labs (NASDAQ:BIOA) Shares Down 7.2% – Should You Sell?

BioAge Labs, Inc. (NASDAQ:BIOA) traded down 7.2% on Friday . The stock traded as low as $22.85 and last traded at $23.1050. Approximately 50,494 shares were traded during mid-day trading, a decline of 92% from the average session volume of 611,441 shares. The stock had previously closed at $24.89.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Needham & Company LLC assumed coverage on shares of BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 price target for the company. BTIG Research assumed coverage on BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price for the company. Roth Capital assumed coverage on BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 target price for the company. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.50.

BioAge Labs Trading Down 4.7%

The business has a 50 day moving average of $19.24 and a 200-day moving average of $18.67. The stock has a market cap of $1.05 billion, a PE ratio of -9.85 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. Research analysts expect that BioAge Labs, Inc. will post -2.68 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Several institutional investors have recently added to or reduced their stakes in BIOA. Russell Investments Group Ltd. acquired a new stake in BioAge Labs during the 3rd quarter worth approximately $27,000. CWM LLC raised its stake in shares of BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after purchasing an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares during the period. Walleye Capital LLC purchased a new position in BioAge Labs in the 2nd quarter valued at $64,000. Finally, Bank of America Corp DE raised its position in BioAge Labs by 46.3% during the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.